Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02622061 · ClinicalTrials.gov registry record

NIOX VERO Nasal Application in Primary Ciliary Dyskinesia

A clinical trial, sponsored by Aerocrine AB.

Completed
Registry status
163
Enrollment target

NCT02622061: Completed study, sponsored by Aerocrine AB.

NCT02622061 is a clinical trial that has completed, run by Aerocrine AB. The registered enrollment target is 163 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02622061 has completed, sponsored by Aerocrine AB.

COMPLETED
Registry status
163 participants
Enrollment target

Study Summary

This is a multi-centre, single visit clinical investigation involving patients with known PCD vs. age matched healthy volunteers. This study involves 1 visit which will last one (1) to two (2) hours. Participants (and parent as applicable) will be asked for their consent to participate in the study. A brief medical history will be recorded, including information such as age, gender, height, weight, race, current medications and living environment. If the participant is a PCD patient, they will also be asked about their disease history. Prior to performing the nasal measurements, participants will receive instructions from study personnel and have the opportunity to practice. All participants will have a brief nasal exam and will also have to blow their nose before starting the measurements. Participants will be asked to perform nasal nitric oxide measurements using the tidal breathing method followed by the velum closed with expiration against resistance method. The primary objective is to determine the feasibility and capability of the NIOX VERO to discriminate participants with PCD from those that are healthy. Information collected in this study will help researchers understand more about the diagnosis of and identification of patients with PCD.

Trial Details

FieldValue
Enrollment Target 163 participants
Start Date 2016-05
Est. Completion 2017-04-28

Sponsor

Aerocrine AB

5 total trials

What the Registry Record Tells You About NCT02622061

The ClinicalTrials.gov registry entry for NCT02622061 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerocrine AB, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02622061 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02622061 about?

NCT02622061 is a clinical study titled "NIOX VERO Nasal Application in Primary Ciliary Dyskinesia". This is a multi-centre, single visit clinical investigation involving patients with known PCD vs. age matched healthy volunteers. This study involves 1 visit which will last one (1) to two (2) hours. Participants (and parent as applicable) will be asked for their consent to participate in the study....

What is the current status of trial NCT02622061?

This trial is currently completed. The enrollment target is 163 participants. The study started on 2016-05. Estimated completion is 2017-04-28.

Who is sponsoring clinical trial NCT02622061?

This trial is sponsored by Aerocrine AB, which has 5 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.